{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:07:50Z","timestamp":1788908870672,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":78,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multidrug-resistant and rifampicin-resistant tuberculosis (MDR\/RR-TB) imposes significant financial burdens on patients. This study aimed to examine the current status of the economic burden of disease in patients with MDR\/RR-TB in Lishui City, Zhejiang Province, and to describe the actual implementation status of the diagnosis-and-treatment subsidy policy and explore associations between subsidy indicators and patient treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective survey of 117 MDR\/RR-TB patients diagnosed and managed in Lishui City from 2017 to 2022. Data on sociodemographic characteristics, diagnosis and treatment processes, medical expenses, and subsidy information were collected and analyzed using questionnaires.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median direct medical expenses (DME) for the 117 patients were Chinese yuan (RMB) 65,182.66 (1 RMB\u2009=\u20090.14 USD). The median amount reimbursed by medical insurance was RMB 40,223.33, and the median out-of-pocket (OOP) payments after medical insurance reimbursement were RMB 21,938.82. The median subsidy amount was RMB 14,405.45, resulting in final OOP payments of RMB 8,167.13. Patients using bedaquiline, linezolid, and clofazimine received higher subsidies compared to non-users (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). Logistic regression analysis showed that subsidy amounts below RMB 14,405.45 were significantly associated with adverse treatment outcomes (95%CI: 0.046\u20130.534, OR\u2009=\u20090.157,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.003). The overall treatment success rate was 75.21%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MDR\/RR-TB patients face a significant economic burden. The findings suggest that the subsidy policy may contribute to reducing out-of-pocket expenditures among MDR\/RR-TB patients; however, further studies using stronger analytical designs are needed to evaluate its effectiveness. Optimizing subsidy criteria, raising subsidy levels and streamlining reimbursement procedures may help relieve patient financial stress, yet relevant benefits require verification via high-quality research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-026-14998-x","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:05:10Z","timestamp":1782216310000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Economic burden of MDR\/RR-TB and implementation of a treatment subsidy policy in Lishui City, China: a retrospective study following strobe guidelines"],"prefix":"10.1186","volume":"26","author":[{"given":"Qian","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Nao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"14998_CR1","unstructured":"World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization; 2021."},{"key":"14998_CR2","unstructured":"World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization; 2023."},{"key":"14998_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2165\/11595340-000000000-00000","volume":"30","author":"C Fitzpatrick","year":"2012","unstructured":"Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. PharmacoEconomics. 2012;30:63\u201380.","journal-title":"PharmacoEconomics"},{"issue":"4","key":"14998_CR4","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2214-109X(15)70021-5","volume":"3","author":"R Li","year":"2015","unstructured":"[4] Li R, Ruan Y, Sun Q, Wang X, Chen M, Zhang H, Zhao Y, Zhao J, Chen C, Xu C, Su W, Pang Y, Cheng J, Chi J, Wang Q, Fu Y, Huan S, Wang L, Wang Y, Chin DP. Effect of a comprehensive programme to provide universal access to care for sputum-smear-positive multidrug-resistant tuberculosis in China: a before-and-after study. Lancet Glob Health. 2015;3(4):e217\u201328.","journal-title":"Lancet Glob Health"},{"key":"14998_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40249-016-0103-3","volume":"5","author":"Q Long","year":"2016","unstructured":"Long Q, Qu Y, Lucas H. Drug-Resistant tuberculosis control in China: progress and challenges. Infect Dis Poverty. 2016;5:9.","journal-title":"Infect Dis Poverty"},{"issue":"1","key":"14998_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12889-017-4089-y","volume":"17","author":"C Hutchison","year":"2017","unstructured":"[6] Hutchison C, Khan MS, Yoong J, Lin X, Coker RJ. Financial barriers and coping strategies: a qualitative study of accessing multidrug-resistant tuberculosis and tuberculosis care in Yunnan, China. BMC Public Health. 2017;17(1):221.","journal-title":"BMC Public Health"},{"issue":"7","key":"14998_CR7","doi-asserted-by":"publisher","first-page":"e1001675","DOI":"10.1371\/journal.pmed.1001675","volume":"11","author":"T Wingfield","year":"2014","unstructured":"Wingfield T, Boccia D, Tovar M, Gavino A, Zevallos K, Montoya R, L\u00f6nnroth K, Evans CA. Defining catastrophic costs and comparing their importance for adverse tuberculosis outcome with multi-drug resistance: a prospective cohort study, Peru. PLoS Med. 2014;11(7):e1001675.","journal-title":"PLoS Med"},{"issue":"1","key":"14998_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-024-00504-2","volume":"10","author":"K Dheda","year":"2024","unstructured":"Dheda K, Mirzayev F, Cirillo DM, et al. Multidrug-resistant tuberculosis. Nat Rev Dis Primers. 2024;10(1):22. https:\/\/doi.org\/10.1038\/s41572-024-00504-2. Published 2024 Mar 24.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"14998_CR9","doi-asserted-by":"publisher","first-page":"e047023","DOI":"10.1136\/bmjopen-2020-047023","volume":"11","author":"W Jiang","year":"2021","unstructured":"Jiang W, Peng Y, Wang X, Elbers C, Tang S, Huang F, Chen B, Cobelens F. Policy changes and the screening, diagnosis and treatment of drug-resistant tuberculosis patients from 2015 to 2018 in Zhejiang Province, China: a retrospective cohort study. BMJ Open. 2021;11(4):e047023. https:\/\/doi.org\/10.1136\/bmjopen-2020-047023.","journal-title":"BMJ Open"},{"issue":"6","key":"14998_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S1473-3099(13)70030-6","volume":"13","author":"I Abubakar","year":"2013","unstructured":"Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, Masham S, Adetifa I, Ford N, Cox H, Lawn SD, Marais BJ, McHugh TD, Mwaba P, Bates M, Lipman M, Zijenah L, Logan S, McNerney R, Zumla A, Sarda K, Nahid P, Hoelscher M, Pletschette M, Memish ZA, Kim P, Hafner R, Cole S, Migliori GB, Maeurer M, Schito M, Zumla A. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis. 2013;13(6):529\u201339.","journal-title":"Lancet Infect Dis"},{"key":"14998_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40249-016-0096-y","volume":"5","author":"S Tang","year":"2016","unstructured":"Tang S, Wang L, Wang H, Chin DP. Access to and affordability of healthcare for TB patients in China: issues and challenges. Infect Dis Poverty. 2016;5:10.","journal-title":"Infect Dis Poverty"},{"issue":"6","key":"14998_CR12","doi-asserted-by":"publisher","first-page":"e0177536","DOI":"10.1371\/journal.pone.0177536","volume":"12","author":"L Wang","year":"2017","unstructured":"Wang L, Li R, Xu C, Zhang H, Ruan Y, Chen M, Wang D, Dirlikov E, Du X, Zhao J, Zhao Y, Wang S, Liu Y, Li L, Falzon D, Sun Y, Wang Y, Schwartl\u00e4nder B, Scano F. The Global Fund in China: Multidrug-resistant tuberculosis nationwide programmatic scale-up and challenges to transition to full country ownership. PLoS ONE. 2017;12(6):e0177536.","journal-title":"PLoS ONE"},{"issue":"4","key":"14998_CR13","first-page":"385","volume":"30","author":"B Chen","year":"2014","unstructured":"Chen B, Wang XM, Zhong JM, Chen SH. Evaluation of the effect of tuberculosis control strategies for rifampicin-resistant tuberculosis in five cities of Zhejiang Province. Chin J Public Health. 2014;30(4):385\u20137.","journal-title":"Chin J Public Health"},{"issue":"5","key":"14998_CR14","first-page":"422","volume":"20","author":"YH Hu","year":"2017","unstructured":"Hu YH, Chen Y, Wu ZY, Zhuang Y, Chen J, Guo JT, Meng W, Shen X. Analysis of the current situation of the implementation of treatment subsidy policy for rifampicin-resistant tuberculosis patients in Shanghai. Chin Health Resour. 2017;20(5):422\u20135.","journal-title":"Chin Health Resour"},{"issue":"10","key":"14998_CR15","first-page":"1768","volume":"17","author":"J Guo","year":"2019","unstructured":"Guo J, Liu ZD, Zhang ZJ, Ye CF, Kong YJ, Zhou GN. Analysis of the current situation of the implementation of treatment subsidy policy for multidrug-resistant tuberculosis patients in Lishui City, Zhejiang Province. Chin J Gen Pract. 2019;17(10):1768\u201372.","journal-title":"Chin J Gen Pract"},{"issue":"1","key":"14998_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40249-020-0623-8","volume":"9","author":"Y Liu","year":"2020","unstructured":"Liu Y, Xu CH, Wang XM, Wang ZY, Wang YH, Zhang H, Wang L. Out-of-pocket payments and economic consequences from tuberculosis care in eastern China: income inequality. Infect Dis Poverty. 2020;9(1):14.","journal-title":"Infect Dis Poverty"},{"issue":"10","key":"14998_CR17","first-page":"1025","volume":"41","author":"Chinese Anti-Tuberculosis Association","year":"2019","unstructured":"Chinese Anti-Tuberculosis Association. Guidelines for the chemotherapy of drug-resistant tuberculosis (2019 simplified version). Chin J Tuberc Respir Dis. 2019;41(10):1025\u201373.","journal-title":"Chin J Tuberc Respir Dis"},{"key":"14998_CR18","unstructured":"World Health Organization. The end TB strategy 2015. Available from: Accessed September 7, 2023. https:\/\/www.who.int\/publications\/i\/item\/WHO-HTM-TB-2015.19. Accessed September."},{"issue":"3","key":"14998_CR19","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.clinthera.2016.01.023","volume":"38","author":"HY Park","year":"2016","unstructured":"Park HY, Ku HM, Sohn HS, Seo HS, Yung Lee H, Hwa Lim K, Kwon JW. Cost-effectiveness of Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the Republic of Korea. Clin Ther. 2016;38(3):655\u201367:e1-2.","journal-title":"Clin Ther"},{"key":"14998_CR20","unstructured":"World Health Organization. Global tuberculosis report 2016; 2016."},{"issue":"7","key":"14998_CR21","doi-asserted-by":"publisher","first-page":"554","DOI":"10.5588\/ijtld.20.0892","volume":"25","author":"T Feuth","year":"2021","unstructured":"Feuth T, Patovirta RL, Grierson S, Danilovits M, Viiklepp P, Aaltonen HK, Vauhkonen M, Pehme L, Vasankari T. Costs of multidrug-resistant TB treatment in Finland and Estonia affected by the 2019 WHO guidelines. Int J Tuberc Lung Dis. 2021;25(7):554\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"02","key":"14998_CR22","first-page":"121","volume":"16","author":"Z Liu","year":"2021","unstructured":"Liu Z, Zhang GL, Gao YL, Fan JQ, Zhang F, Zhao K, Liu YH. Research on the Supply Situation of the Second-line Anti-Tuberculosis Drugs in 5 Provinces & Cities and Policy Suggestion. PharmacoEconomics. 2021;16(02):121\u20134.","journal-title":"PharmacoEconomics"},{"key":"14998_CR23","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.2147\/RMHP.S420082","volume":"16","author":"M Zhou","year":"2023","unstructured":"Zhou M, Peng Y, Liu K, Zhou L, Wang F, Chen X, Chen B, Hu C. Direct Medical Expenses and Influencing Factors of MDR\/RR-TB in Eastern China: Based on Data from Multi-Hospital Information Systems. Risk Manag Healthc Policy. 2023;16:1955\u201365.","journal-title":"Risk Manag Healthc Policy"},{"key":"14998_CR24","unstructured":"Zhang GC. Analysis of the economic burden of multidrug-resistant tuberculosis in guangzhou and the factors affecting it. Guangdong University of Pharmaceutical Sciences; 2021."},{"issue":"1","key":"14998_CR25","doi-asserted-by":"publisher","first-page":"22361","DOI":"10.1038\/s41598-023-47094-9","volume":"13","author":"TY Akalu","year":"2023","unstructured":"Akalu TY, Clements ACA, Wolde HF, Alene KA. Economic burden of multidrug-resistant tuberculosis on patients and households: a global systematic review and meta-analysis. Sci Rep. 2023;13(1):22361.","journal-title":"Sci Rep"},{"issue":"04","key":"14998_CR26","first-page":"441","volume":"20","author":"JL Ye","year":"2020","unstructured":"Ye JL, Wu HZ, Zou X, Chen L, Zhou FJ, Kuang HB, Zhou L, Ling L. Analysis of factors influencing the economic burden of 162 patients with multidrug-resistant tuberculosis. J Trop Med. 2020;20(04):441\u20135.","journal-title":"J Trop Med"},{"key":"14998_CR27","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.2147\/IDR.S484268","volume":"18","author":"H Luo","year":"2025","unstructured":"Luo H, Ma J, He X, et al. Impact of Patient-Centered Care on Treatment Outcomes of Multidrug-Resistant\/Rifampicin-Resistant Tuberculosis in Xi\u2019an. Infect Drug Resist. 2025;18:1425\u201337. https:\/\/doi.org\/10.2147\/IDR.S484268. Published 2025 Mar 13.","journal-title":"Infect Drug Resist"},{"key":"14998_CR28","doi-asserted-by":"publisher","unstructured":"Gao J, Gao M, Du J, et al. A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT. Trials. 2024;25(1):227. Published 2024 Apr 1. https:\/\/doi.org\/10.1186\/s13063-024-07946-9.","DOI":"10.1186\/s13063-024-07946-9"},{"key":"14998_CR29","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. 2022. Available from: Accessed September 7, 2023. https:\/\/www.who.int\/publications\/i\/item\/9789240063129. Accessed September 7, 2023."},{"issue":"21","key":"14998_CR30","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.3346\/jkms.2023.38.e167","volume":"38","author":"HY Park","year":"2023","unstructured":"Park HY, Kwon JW, Kim HL, et al. Cost-Effectiveness of All-Oral Regimens for the Treatment of Multidrug-Resistant Tuberculosis in Korea: Comparison With Conventional Injectable-Containing Regimens. J Korean Med Sci. 2023;38(21):e167. https:\/\/doi.org\/10.3346\/jkms.2023.38.e167. Published 2023 May 29.","journal-title":"J Korean Med Sci"},{"key":"14998_CR31","doi-asserted-by":"publisher","first-page":"1201512","DOI":"10.3389\/fpubh.2024.1201512","volume":"12","author":"S Nagar","year":"2024","unstructured":"Nagar S, Nicholls D, Dawoud D. A systematic review of economic evaluations of pharmacological treatments for active tuberculosis. Front Public Health. 2024;12:1201512. https:\/\/doi.org\/10.3389\/fpubh.2024.1201512. Published 2024 Apr 16.","journal-title":"Front Public Health"},{"key":"14998_CR32","volume-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva, Switzerland: WHO; 2019."},{"issue":"10","key":"14998_CR33","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie F, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893\u2013902.","journal-title":"N Engl J Med"},{"key":"14998_CR34","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/S0140-6736(19)32399-2","volume":"394","author":"T Wei","year":"2019","unstructured":"Wei T, Feng W. Impact analysis of the payment reform of same disease with the same price in the same level of hospital diagnosis-related group based on L City, Guizhou Province: an empirical study. Lancet. 2019;394:S63. https:\/\/doi.org\/10.1016\/S0140-6736(19)32399-2.","journal-title":"Lancet"},{"issue":"10362","key":"14998_CR35","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/S0140-6736(22)01883-9","volume":"400","author":"J Mok","year":"2022","unstructured":"Mok J, Lee M, Kim DK, Kim JS, Jhun BW, Jo KW, Jeon D, Lee T, Lee JY, Park JS, Lee SH, Kang YA, Lee JK, Kwak N, Ahn JH, Shim TS, Kim SY, Kim S, Kim K, Seok KH, Yoon S, Kim YR, Kim J, Yim D, Hahn S, Cho SN, Yim JJ. MDR-END investigators. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2\/3 non-inferiority trial in South Korea. Lancet. 2022;400(10362):1522\u201330.","journal-title":"Lancet"},{"key":"14998_CR36","unstructured":"Li R. A comparative study on the effectiveness of MDR-TB control before and after the completion of the Global Fund MDR-TB control project in Shandong Province. Shandong University; 2019."},{"issue":"10125","key":"14998_CR37","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S0140-6736(18)30563-4","volume":"391","author":"[37] The Lancet","year":"2018","unstructured":"[37] The Lancet. China through the lens of health in 2018 and beyond. Lancet. 2018;391(10125):999.","journal-title":"Lancet"},{"issue":"8","key":"14998_CR38","doi-asserted-by":"publisher","first-page":"e0135802","DOI":"10.1371\/journal.pone.0135802","volume":"10","author":"RD Deshmukh","year":"2015","unstructured":"Deshmukh RD, Dhande DJ, Sachdeva KS, Sreenivas A, Kumar AM, Satyanarayana S, Parmar M, Moonan PK, Lo TQ. Patient and Provider Reported Reasons for Lost to Follow Up in MDRTB Treatment: A Qualitative Study from a Drug Resistant TB Centre in India. PLoS ONE. 2015;10(8):e0135802.","journal-title":"PLoS ONE"},{"issue":"1","key":"14998_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.15975\/j.cnki.gsyy.2016.01.029","volume":"35","author":"XM Tian","year":"2016","unstructured":"Tian XM, Ma BJ, Wang XL, Shi F. Analysis of the current situation of the medical compensation policy for rifampicin-resistant tuberculosis patients in Ningxia Hui Autonomous Region. Gansu Med J. 2016;35(1):61\u20134. https:\/\/doi.org\/10.15975\/j.cnki.gsyy.2016.01.029.","journal-title":"Gansu Med J"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-14998-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14998-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14998-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:43:05Z","timestamp":1788907385000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-14998-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14998"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-14998-x","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. The study was approved by Ethics Committee of the Lishui Hospital of Traditional Chinese Medicine (No.LW-2024029). All participants provided written informed consent for their involvement in the study. In cases where participants were under the age of 18, informed consent was additionally obtained from their parents or legal guardians.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1249"}}